Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUPINE: Lurbinectedin + Paclitaxel vs Paclitaxel in Previously Treated SCLC
NCT07640932Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Nov 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in small cell lung cancer (SCLC), sponsored by Yonsei University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07640932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640932.